Description：

Cobimetinib (trade name Cotellic) is a MEK inhibitor developed by Exelixis and Genentech. It is used in combination with vemurafenib, a BRAF inhibitor, to treat melanoma. In November 2015, the U.S. Food and Drug Administration approved cobimetinib for unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib (Zelboraf). Cobimetinib is not indicated for treatment of patients with wild-type BRAF melanoma.
Cobimetinib in combination with vemurafenib is reportedly priced at $17,600 per month, or about $211,000 per year. A competing dual therapy, using dabrafenib along with trametinib, is also approved by the FDA, and is reported to cost $15,300 monthly, or $183,600 per year.

We can provide this product with purity 99%.

The test result of COA

ProductName: Cobimetinib

Cas:       934660-93-2

Batch No.:    20171012

MFG Date:  Oct.12.2017

Analysis Date:Oct.12.2017

Cobimetinib CAS No.: 934660-93-2 as a new drug development, Hangzhou Shitai Biotech Co., Ltd has completed all the pre production work of the project, including laboratory synthesis phase and possible impurity analysis work. In the second half of 2017, we completed the experiment on the Chinese production of Cobimetinib products. The technical requirements of large production are analyzed and summarized. At present, the product's stability and purity and other information are in line with the customer's requirements. In the future, we want to cooperate with the advanced pharmaceutical companies in the world to bring the products into the GMP production requirements. At the same time, we should also begin to prepare for the requirements of the DMF file. All pharmaceutical companies are welcome to visit and cooperate.